Estimated potassium intake and major adverse cardiovascular events in individuals with type 2 diabetes: a prospective cohort study with trans-ethnic validation
Main finding · MACE (discovery cohort)Result — go to the resultAdjusted hazard ratio 0.66 95% CI 0.49–0.89Authors' conclusion
A high level potassium intake estimated from urine potassium excretion was independently associated with a low risk of MACE in patients with type 2 diabetes. Increasing potassium intake may be a potential effective strategy for cardiovascular risk reduction beyond controlling traditional risk factors.
Study context
- Population
- Individuals with T2D from a secondary hospital (discovery cohort); validation in participants with diabetes from the multicenter CRIC study; potassium intake estimated from spot urine (Kawasaki formula) and 24-h urine, respectivelydiscovery cohort
- Participants
- 1,572 individuals
- Exposure
- Top vs lowest tertile of estimated potassium intake
- Outcome
- MACE: composite of MI, stroke and cardiovascular death
- Follow-up
- Median 8.2 years
Methodological detailstrans-ethnic validation, discovery and validation cohorts
- Trans-ethnic validation
- Discovery and validation cohorts
Main finding
MACE (discovery cohort) · median 8.2 years
Adjusted hazard ratio
0.66
95% CI 0.49–0.89
Top tertilevs Lowest tertile
aHR 0.66 (95% CI 0.49–0.89)
As reported in the abstract
- Major cardiovascular events (MACE) events in discovery cohort
- 341
Observational data: associations, not effects.
Further findings
| Outcome | aHR (CI) | |
|---|---|---|
| MACE in CRIC participants with diabetes and moderately elevated albuminuria (validation cohort) | 0.61 (0.42–0.90) | |
| 0.512Adjusted hazard ratio (log scale) |
MACE by albuminuria subgroup (discovery cohort)
- Inverse association more pronounced with normal or moderately elevated albuminuria vs severely elevated albuminuria (urine albumin-to-creatinine ratio > 300 mg/g)
- P for interaction < 0.05
Original publication
Estimated potassium intake and major adverse cardiovascular events in individuals with type 2 diabetes: a prospective cohort study with trans-ethnic validation. Cardiovasc Diabetol. Published 21 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →